YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial
Year: 2021
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background: YF-H-2015005, a novel CXCR4 antagonist, has been proven to increase the quantities of circulating hematopoietic stem cells (HSCs), which results in an adequate collection of HSCs in non-Hodgkin lymphoma (NHL) patients. Methods: This was a multicenter, double-blind, randomized (1:1), placebo-controlled phase III clinical trial. All patients received granulocyte colony-stimulating factor (G-CSF) for up to 8 consecutive days. YF-H-2015005 or placebo was administrated on the evening of day 4 and continued daily for up to 4 days. Apheresis was conducted 9–10 h after each dose of YF-H-2015005 or placebo. The primary endpoint was the proportion of NHL patients procuring ≥5 × 106/kg CD34+ HSCs within ≤4 apheresis sessions. Results: In total, 101 patients with NHL were enrolled. The proportions of patients achieving primary endpoint were 57 and 12% in YF-H-2015005 and placebo groups, respectively (P < 0.001). Moreover, a higher proportion of YF-H-2015005-treated patients reached a minimum target collection of ≥2 × 106/kg CD34+ HSCs in ≤4 apheresis days compared to placebo-treated patients (86 vs. 38%, P < 0.001). Furthermore, the median time to collect ≥2 or 5 × 106/kg CD34+ HSCs were 1 and 3 days in YF-H-2015005-treated patients, but 4 days and not reached in placebo-treated patients, respectively. No severe treatment emergent adverse events were observed in both YF-H-2015005 treatment and placebo groups. Conclusions: YF-H-2015005 plus G-CSF regimen was a tolerable combination with high efficacy, which might be used to rapidly mobilize and collect HSCs in NHL patients.
Source: Frontiers in Medicine
Authors: Weiping Liu, Yufu Li, Quanshun Wang, Hang Su, Kaiyang Ding, Yuerong Shuang, Sujun Gao, Dehui Zou, Hongmei Jing, Ye Chai, Yicheng Zhang, Lihong Liu, Chunling Wang, Hui Liu, Jinying Lin, Haiyan Zhu, Chen Yao, Xiaoyan Yan, Meixia Shang, Shufang Wang, Fengyuan Chang, Xiaopei Wang, Jun Zhu, Yuqin Song
Institutions: Peking University Cancer Hospital, Henan Cancer Hospital, Chinese PLA General Hospital, Chinese People's Liberation Army, Jiangxi Provincial Cancer Hospital, First Hospital of Jilin University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking University Third Hospital, Lanzhou University Second Hospital, Huazhong University of Science and Technology, Fourth Hospital of Hebei Medical University, Huaian First People’s Hospital, Nanjing Medical University, Beijing Hospital, The People's Hospital of Guangxi Zhuang Autonomous Region, Peking University First Hospital, Peking University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
OpenAlex ID: W3127020718
